আর্মেনিয়া - ইংরেজি - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals sa - live attenuated measles virus(schwarz strain), live attenuated mumps virus(rit 4385 strain), live attenuated rubella virus(wistar ra 27/3 strain) - powder and solvent for solution for injection - not less than 103.0ccid50/dose+ not less than 103.7ccid50/dose+ not less than 103.0ccid50/dose

সংযুক্ত আরব আমিরাত - ইংরেজি - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

live attenuated measles virus (schwarz strain) no less than, live attenuated rubella virus (wistar ra 27/3 strain), live attenuated mumps virus (rit 4385 strain, derived from jeryl lynn strain) no less than, live attenuated varicella virus (oka strain) no less than -

সংযুক্ত আরব আমিরাত - ইংরেজি - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

live attenuated rubella virus (wistar ra 27/3 strain) [not less than 10^3 ccid^3 -50], live attenuated mumps virus (rit 4385 strain, derived from jeryl lynn strain) [not less than 10^3.7 ccid^3 -50], live attenuated measles virus (schwarz strain) [not less than 10^3 ccid^3 -50] -

মাল্টা - ইংরেজি - Medicines Authority

nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - powder and solvent for solution for injection - measles virus - schwarz strain 50 % mumps virus jeryl lynn (level b) strain (live, attenuated) 50 % rubella virus - wistar ra27/3 strain 50 % - vaccines

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - rubella virus live attenuated; mumps virus live attenuated; measles virus live attenuated - powder and solvent for solution for injection

কানাডা - ইংরেজি - Health Canada

merck canada inc - measles virus vaccine live attenuated; mumps virus vaccine live attenuated (jeryl lynn strain); rubella virus vaccine live attenuated (wistar ra27/3 strain) - powder for solution - 1000unit; 5000unit; 1000unit - measles virus vaccine live attenuated 1000unit; mumps virus vaccine live attenuated (jeryl lynn strain) 5000unit; rubella virus vaccine live attenuated (wistar ra27/3 strain) 1000unit - vaccines

সিঙ্গাপুর - ইংরেজি - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - measles virus (schwarz strain) (live attenuated); mumps virus (rit 4385 strain) (live attenuated); rubella virus (ra27/3 strain) (live attenuated) - injection, powder, for solution - min 1000 tcid50 - measles virus (schwarz strain) (live attenuated) min 1000 tcid50; mumps virus (rit 4385 strain) (live attenuated) min 5000 tcid50; rubella virus (ra27/3 strain) (live attenuated) min 1000 tcid50

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - measles virus strain schwartz attenuated chick embryo fibroblasts live antigen (unii: yrf2uzg52m) (measles virus strain schwartz attenuated chick embryo fibroblasts live antigen - unii:yrf2uzg52m), mumps virus strain rit-4385 attenuated chick embryo fibroblasts live antigen (unii: 566fj5l8r4) (mumps virus strain rit-4385 attenuated chick embryo fibroblasts live antigen - unii:566fj5l8r4), rubella virus strain wistar ra 27/3 live antigen (unii: 52202h034z) (rubella virus strain wistar ra 27/3 live antigen - unii:52202h034z) - priorix is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. do not administer priorix to individuals with a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of any measles, mumps, and rubella virus-containing vaccine [see description (11)] . due to the risk of disseminated vaccine virus infection, do not administer priorix to individuals with severe humoral or cellular (primary or acquired) immunodeficiency. do not administer priorix to individuals who are pregnant. pregnancy should be avoided for 1 month after vaccination [see use in specific populations (8.1)] . risk summary priorix contains live attenuated measles, mumps, and rubella viruses. the vaccine is contraindicated for use in pregnant women because infection during pregnancy with the wild-type viruses is associated with maternal and fetal adverse outcomes. pregnancy should be avoided for 1 month after vaccination [see contraindications (4.3), patient counseling information (17)]. reports have indicated that contracting wild-type measles during pregnancy enhances fetal risk, including increased rates of spontaneous abortion, stillbirth, premature delivery and congenital defects.2,3 wild-type mumps virus infection during the first trimester of pregnancy may increase the rate of spontaneous abortion. pregnant women infected with wild-type rubella virus are at increased risk for miscarriage or stillbirth, and their infants are at risk for congenital rubella syndrome.1 available data on inadvertent administration of priorix to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. there are no animal studies with priorix to inform use during pregnancy. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary it is not known whether the vaccine components of priorix are excreted in human milk. data are not available to assess the effects of priorix on the breastfed infant or on milk production/excretion. studies have shown that lactating postpartum women vaccinated with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breast‑fed infants.4,5 in the breast-fed infants with serological evidence of rubella virus vaccine strain antibodies, none exhibited severe disease; however, one exhibited mild clinical illness typical of acquired rubella.6,7 the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for priorix and any potential adverse effects on the breastfed child from priorix or from the underlying maternal condition. for preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine. safety and effectiveness of priorix in infants younger than 12 months have not been established. clinical studies of priorix did not include participants 65 years of age and older to determine whether they respond differently from younger participants.

মাল্যাশিয়া - ইংরেজি - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - live attenuated measles virus; live attenuated rubella virus; live attenuated mumps virus; live attenuated varicella oka strain virus -

মাল্যাশিয়া - ইংরেজি - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - live attenuated measles virus; live attenuated mumps virus; live attenuated rubella virus; live attenuated varicella oka strain virus -